Inflammatory Bowel Disease Therapeutics on the Rise

10 Pages

Inflammatory Bowel Disease (IBD) drug development is accelerating as unmet need persists across ulcerative colitis and Crohn’s disease. This paper maps today’s standard-of-care and then profiles the evolving clinical-trial landscape, highlighting where activity is concentrated, which mechanisms are gaining traction, and how pipelines differ by indication and disease stage. It reviews the pipeline for UC and CD, calls out novel therapies in early development, and summarizes what’s driving momentum and where key gaps remain.

Join for free to read

Case Study Use of AI-enhanced data analysis to identify persons at risk of…

Case Study Acorda Therapeutics

Case Study Neurodegenerative Disease Research

Case Study Capturing and Managing Data in Digital Therapeutics Trials

More from IQVIA

White Paper Harnessing the Multitudes: Charting the Future of Microbiome…

White Paper Mind Matters: Shining the spotlight on Alzheimer’s Disease in…

Ebook Alzheimer’s Disease Clinical Trials

Case Study IQVIA eCOA Delivers on a Tight Timeline for a Sickle Cell…

White Paper

Inflammatory Bowel Disease Therapeutics on the Rise

Inflammatory Bowel Disease Therapeutics on the Rise

You Might Also Like

More from IQVIA